Pharmaceuticals Industry Update - Indian Companies To Demonstrate Healthy Growth & Margins In FY22: ICRA

Technicians work at a vial washing unit at a pharmaceutical plant in Pune. (Photographer: Sanjit Das/Bloomberg)

Pharmaceuticals Industry Update - Indian Companies To Demonstrate Healthy Growth & Margins In FY22: ICRA

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICRA Report

The impact of Covid-19 on Indian Pharmaceuticals Market has been relatively limited in FY 2021 owing to inelastic demand for pharmaceutical products and resumption of imports of key input materials from China from March 2020 onwards.

However, some impact on volume growth was felt owing to lockdowns (lesser OPDs/elective surgeries)

Revenue growth for ICRA sample of 21 companies and IPM remained muted in FY 2021 at 5.8% and ~3%, respectively, though the same witnessed a growth on a year-on-year basis despite Covid-19 related disruptions.

Growth was supported by depreciation of the INR vis-à-vis USD/GBP/EUR.

Click on the attachment to read the full report:

ICRA Pharmaceutical Industry Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.